The impact of pharmaceutical care on patients with hypertension and their pharmacists

  • Agnieszka Skowron
  • Sebastian Polak
  • Jerzy Brandys


Objective: The purpose of the study was to assess the influence of pharmaceutical care on patients’ knowledge, quality of life and blood pressure and to determine whether new type of pharmaceutical services changes the pharmacists’ satisfaction and knowledge.

Methods: Community pharmacies were randomly assigned to study and control group and pharmacists from both groups included patients with hypertension, who meet inclusion and exclusion criteria. Study group provided the pharmaceutical care (education, pharmacotherapy monitoring, detecting and solving drug related problems) for their patients, while the control group provided the standard pharmaceutical services (dispensing medicines with or without counseling). At the beginning and the end of the study pharmacists and patients filled in the knowledge test. Pharmacists fulfilled also satisfaction questionnaire.

Results: Survey data were collected from 28 and 56 patients from community pharmacies in study and control group respectively. At the last meeting the normal blood pressure achieved 79% and 55% patients in study and control group, respectively (p>0,05). The pharmaceutical care improved patients’ knowledge about disease. Pharmacists from study group, who provided pharmaceutical care, had higher level of pharmacotherapy knowledge and professional satisfaction than the control group.

Conclusion: Implementation of pharmaceutical care into the pharmacy practice benefits both, patients and pharmacists.


Keywords: Hypertension. Medication Therapy Management. Community Pharmacy Services. Poland.


Download data is not yet available.


1. Borzecki AM, Oliveria SA, Berlowitz DR. Barriers to hypertension control. Am Heart J. 2005;149(5):785-794.

2. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-1963.

3. Degli Esposti E, Di Martino M, Sturani A, Russo P, Dradi C, Falcinelli S, Buda S. Risk factors for uncontrolled hypertension in Italy. J Hum Hypertens. 2004;18(3):207-213.

4. Jokisalo E, Kumpusalo E, Enlund H, Takala J. Patients' perceived problems with hypertension and attitudes towards medical treatment. J Hum Hypertens. 2001;15(11):755-761.

5. Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. Achieving better blood pressure control. Blood Press Suppl. 2008;1:3-4.

6. Harmon G, Lefante J, Krousel-Wood M. Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications. Curr Opin Cardiol. 2006;21(4):310-315.

7. Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med. 1998;13(11):740-745.

8. Cuspidi C, Meani S, Fusi V, Salerno M, Valerio C, Severgnini B, Catini E, Leonetti G, Magrini F, Zanchetti A. Home blood pressure measurement and its relationship with blood pressure control in a large selected hypertensive population. J Hum Hypertens. 2004;18(10):725-731.

9. Jones DW, Peterson ED. Improving hypertension control rates: technology, people, or systems? JAMA. 2008;299(24):2896-2898.

10. Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, Touchette D. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23(12):1966-1972.

11. Von Muenster SJ, Carter BL, Weber CA, Ernst ME, Milchak JL, Steffensmeier JJ, Xu Y. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci. 2008;30(1):128-135.

12. McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, Tsuyuki RT. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;168(21):2355-2361.

13. Chabot I, Moisan J, Gregoire JP, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother. 2003;37(9):1186-1193.

14. Cote I, Moisan J, Chabot I, Gregoire JP. Health-related quality of life in hypertension: impact of a pharmacy intervention program. J Clin Pharm Ther. 2005;30(4):355-362.

15. Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, Carrell D, Tyll L, Larson EB, Thompson RS. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008;299(24):2857-2867.

16. Green BB, Ralston JD, Fishman PA, Catz SL, Cook A, Carlson J, Tyll L, Carrell D, Thompson RS. Electronic communications and home blood pressure monitoring (e-BP) study: design, delivery, and evaluation framework. Contemp Clin Trials. 2008;29(3):376-395.

17. Erhun WO, Agbani EO, Bolaji EE. Positive benefits of a pharmacist-managed hypertension clinic in Nigeria. Public Health. 2005;119(9):792-798.

18. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000;20(11):1384-1389.

19. McConnell KJ, Zadvorny EB, Hardy AM, Delate T, Rasmussen JR, Merenich JA. Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program. Pharmacotherapy. 2006;26(9):1333-1341.

20. Reid F, Murray P, Storrie M. Implementation of a pharmacist-led clinic for hypertensive patients in primary care--a pilot study. Pharm World Sci. 2005;27(3):202-207.

21. Aguwa CN, Ukwe CV, Ekwunife OI. Effect of pharmaceutical care program on blood pressure and quality of life in a Nigerian pharmacy. Pharm World Sci. 2008;30(1):107-110.

22. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med. 2005;20(12):1091-1096.

23. Hepler Ch., Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533–554.

24. Ware JE., Sherbourne CD. The MOS 36-item short-form Health Survey (SF-36): I. Conceptual Framework and Item Selection, Med Care. 1992;30(6):473-483.

25. Ware JE, Kosinski M, Dewey JE. How to score Version 2 of the SF-36 Health Survey (Standard & Acute Forms). Lincoln, TI: QualityMetric Incorporated, 2000.

26. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751-1762.

27. Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health. 1983;73(2):153-162.

28. Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 1997;17(6):1274-1285.

29. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997;17(1):140-147.

30. Villeneuve J, Lamarre D, Lussier MT, Vanier MC, Genest J, Blais L, Hudon E, Perreault S, Berbiche D, Lalonde L. Physician-pharmacist collaborative care for dyslipidemia patients: knowledge and skills of community pharmacists. J Contin Educ Health Prof. 2009;29(4):201-208.

31. Collins C, Kramer A, O'Day ME, Low MB. Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center. Am J Health Syst Pharm. 2006;63(18):1723-1727.

32. Lapane KL, Hughes CM. Baseline job satisfaction and stress among pharmacists and pharmacy technicians participating in the Fleetwood Phase III Study. Consult Pharm. 2004;19(11):1029-1037.
Original Research